메뉴 건너뛰기




Volumn 216, Issue 11, 2017, Pages 1352-1361

Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older

Author keywords

Adjuvant; Coadministration; Herpes zoster; Influenza; Subunit vaccine

Indexed keywords

GLYCOPROTEIN E; GSK 1437173A; INFLUENZA VACCINE; PROTEIN ANTIBODY; VARICELLA ZOSTER VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; PHARMACEUTICAL VEHICLES AND ADDITIVES; SUBUNIT VACCINE; VIRUS ANTIBODY;

EID: 85038641466     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix481     Document Type: Conference Paper
Times cited : (66)

References (26)
  • 1
    • 84886735328 scopus 로고    scopus 로고
    • Herpes zoster
    • Cohen JI. Herpes zoster. N Engl J Med 2013; 369:1766-7.
    • (2013) N Engl J Med , vol.369 , pp. 1766-1767
    • Cohen, J.I.1
  • 2
    • 21144448596 scopus 로고    scopus 로고
    • A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    • Oxman MN, Levin MJ, Johnson GR, et al.; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
    • (2005) N Engl J Med , vol.352 , pp. 2271-2284
    • Oxman, M.N.1    Levin, M.J.2    Johnson, G.R.3
  • 4
    • 84946576290 scopus 로고    scopus 로고
    • Annual incidence rates of herpes zoster among an immunocompetent population in the United States
    • Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015; 15:502.
    • (2015) BMC Infect Dis , vol.15 , pp. 502
    • Johnson, B.H.1    Palmer, L.2    Gatwood, J.3    Lenhart, G.4    Kawai, K.5    Acosta, C.J.6
  • 5
    • 35848954757 scopus 로고    scopus 로고
    • A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction
    • Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341-9.
    • (2007) Mayo Clin Proc , vol.82 , pp. 1341-1349
    • Yawn, B.P.1    Saddier, P.2    Wollan, P.C.3    St Sauver, J.L.4    Kurland, M.J.5    Sy, L.S.6
  • 6
    • 81755178307 scopus 로고    scopus 로고
    • Update on herpes zoster vaccine: Licensure for persons aged 50 through 59 years
    • Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep 2011; 60:1528.
    • (2011) MMWR Morb Mortal Wkly Rep , vol.60 , pp. 1528
  • 7
    • 44849103815 scopus 로고    scopus 로고
    • Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • quiz CE2-4
    • Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1-30; quiz CE2-4.
    • (2008) MMWR Recomm Rep , vol.57 , pp. 1-30
    • Harpaz, R.1    Ortega-Sanchez, I.R.2    Seward, J.F.3
  • 8
    • 84863289439 scopus 로고    scopus 로고
    • Efcacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years
    • Schmader KE, Levin MJ, Gnann JW Jr, et al. Efcacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8.
    • (2012) Clin Infect Dis , vol.54 , pp. 922-928
    • Schmader, K.E.1    Levin, M.J.2    Gnann, J.W.3
  • 9
    • 84958757307 scopus 로고    scopus 로고
    • Long-term immu-nogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
    • Chlibek R, Pauksens K, Rombo L, et al. Long-term immu-nogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 2016; 34:863-8.
    • (2016) Vaccine , vol.34 , pp. 863-868
    • Chlibek, R.1    Pauksens, K.2    Rombo, L.3
  • 10
    • 84929850029 scopus 로고    scopus 로고
    • Efcacy of an adjuvanted herpes zoster subunit vaccine in older adults
    • Lal H, Cunningham AL, Godeaux O, et al.; ZOE-50 Study Group. Efcacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087-96.
    • (2015) N Engl J Med , vol.372 , pp. 2087-2096
    • Lal, H.1    Cunningham, A.L.2    Godeaux, O.3
  • 11
    • 84988446438 scopus 로고    scopus 로고
    • Efcacy of the herpes zoster subunit vaccine in adults 70 years of age or older
    • Cunningham AL, Lal H, Kovac M, et al.; ZOE-70 Study Group. Efcacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:1019-32.
    • (2016) N Engl J Med , vol.375 , pp. 1019-1032
    • Cunningham, A.L.1    Lal, H.2    Kovac, M.3
  • 12
    • 84886257168 scopus 로고    scopus 로고
    • Prevention and control of seasonal infuenza with vaccines
    • Centers for Disease Control and Prevention. Prevention and control of seasonal infuenza with vaccines. MMWR Recomm Rep 2013; 62:1-43.
    • (2013) MMWR Recomm Rep , vol.62 , pp. 1-43
  • 13
    • 84871853038 scopus 로고    scopus 로고
    • Vaccines against infuenza WHO position paper-November 2012
    • World Health Organization. Vaccines against infuenza WHO position paper-November 2012. Wkly Epidemiol Rec 2012; 87:461-76.
    • (2012) Wkly Epidemiol Rec , vol.87 , pp. 461-476
  • 14
    • 84877841776 scopus 로고    scopus 로고
    • Immunogenicity and safety of quadrivalent versus trivalent inactivated infuenza vaccine: A randomized, controlled trial in adults
    • Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM. Immunogenicity and safety of quadrivalent versus trivalent inactivated infuenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013; 13:224.
    • (2013) BMC Infect Dis , vol.13 , pp. 224
    • Beran, J.1    Peeters, M.2    Dewé, W.3    Raupachová, J.4    Hobzová, L.5    Devaster, J.M.6
  • 15
    • 0034257236 scopus 로고    scopus 로고
    • Antibody response to infuenza immunization in two consecutive epidemic seasons in patients with renal diseases
    • Brydak LB, Roszkowska-Blaim M, Machala M, Leszczynska B, Sieniawska M. Antibody response to infuenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine 2000; 18:3280-6.
    • (2000) Vaccine , vol.18 , pp. 3280-3286
    • Brydak, L.B.1    Roszkowska-Blaim, M.2    MacHala, M.3    Leszczynska, B.4    Sieniawska, M.5
  • 16
    • 51449110453 scopus 로고    scopus 로고
    • Correlates of protection: Novel generations of infuenza vaccines
    • Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of infuenza vaccines. Vaccine 2008; 26 (suppl 4):D41-4.
    • (2008) Vaccine , vol.26 , pp. D41-D44
    • Rimmelzwaan, G.F.1    McElhaney, J.E.2
  • 18
    • 43449112670 scopus 로고    scopus 로고
    • Efects of repeated annual infuenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers
    • Iorio AM, Camilloni B, Basileo M, Neri M, Lepri E, Spighi M. Efects of repeated annual infuenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology 2007; 53:411-8.
    • (2007) Gerontology , vol.53 , pp. 411-418
    • Iorio, A.M.1    Camilloni, B.2    Basileo, M.3    Neri, M.4    Lepri, E.5    Spighi, M.6
  • 19
    • 33846804082 scopus 로고    scopus 로고
    • Antibody response to infuenza vaccine in adults vaccinated with identical vaccine strains in consecutive years
    • Nabeshima S, Kashiwagi K, Murata M, Kanamoto Y, Furusyo N, Hayashi J. Antibody response to infuenza vaccine in adults vaccinated with identical vaccine strains in consecutive years. J Med Virol 2007; 79:320-5.
    • (2007) J Med Virol , vol.79 , pp. 320-325
    • Nabeshima, S.1    Kashiwagi, K.2    Murata, M.3    Kanamoto, Y.4    Furusyo, N.5    Hayashi, J.6
  • 20
    • 0028022941 scopus 로고
    • Immune response to infuenza vaccination of elderly people. A randomized double-blind placebo-controlled trial
    • Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to infuenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994; 12:1185-9.
    • (1994) Vaccine , vol.12 , pp. 1185-1189
    • Govaert, T.M.1    Sprenger, M.J.2    Dinant, G.J.3    Aretz, K.4    Masurel, N.5    Knottnerus, J.A.6
  • 21
    • 85008339535 scopus 로고    scopus 로고
    • Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent infuenza vaccine: A phase III, open-label study of adults in Brazil
    • Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, et al. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent infuenza vaccine: a phase III, open-label study of adults in Brazil. Braz J Infect Dis 2017; 21:63-70.
    • (2017) Braz J Infect Dis , vol.21 , pp. 63-70
    • Zerbini, C.A.1    Ribeiro Dos Santos, R.2    Jose Nunes, M.3
  • 22
    • 84862776821 scopus 로고    scopus 로고
    • The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more efective infuenza vaccines
    • McElhaney JE, Zhou X, Talbot HK, et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more efective infuenza vaccines. Vaccine 2012; 30:2060-7.
    • (2012) Vaccine , vol.30 , pp. 2060-2067
    • McElhaney, J.E.1    Zhou, X.2    Talbot, H.K.3
  • 24
    • 84965178537 scopus 로고    scopus 로고
    • Influence of statins on infuenza vaccine response in elderly individuals
    • Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of statins on infuenza vaccine response in elderly individuals. J Infect Dis 2016; 213:1224-8.
    • (2016) J Infect Dis , vol.213 , pp. 1224-1228
    • Black, S.1    Nicolay, U.2    Del Giudice, G.3    Rappuoli, R.4
  • 25
    • 79960332418 scopus 로고    scopus 로고
    • A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given con-comitantly with trivalent infuenza vaccine in adults aged ≥65 years
    • Schwarz TF, Flamaing J, Rümke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given con-comitantly with trivalent infuenza vaccine in adults aged ≥65 years. Vaccine 2011; 29:5195-202.
    • (2011) Vaccine , vol.29 , pp. 5195-5202
    • Schwarz, T.F.1    Flamaing, J.2    Rümke, H.C.3
  • 26
    • 85046915712 scopus 로고    scopus 로고
    • Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with infuenza vaccine in adults
    • Weston WM, Chandrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with infuenza vaccine in adults. Hum Vaccin 2009; 5:858-66.
    • (2009) Hum Vaccin , vol.5 , pp. 858-866
    • Weston, W.M.1    Chandrashekar, V.2    Friedland, L.R.3    Howe, B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.